ARS PHARMACEUTICALS, INC.
StreetZero Signal 59
About ARS PHARMACEUTICALS, INC.
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a commercial-stage biopharmaceutical company focused on developing and commercializing needle-free emergency treatments for Type I severe allergic reactions, including anaphylaxis. Its lead product is neffy, the first FDA-approved needle-free epinephrine nasal spray. The company is headquartered in San Diego, California and was founded in 2015.
LATEST FUNDINGRule 144
$410K
Announced 2026-10-19
IN THE NEWS
- 🔗 ARS Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 ARS Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 ARS Pharmaceuticals, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 ARS Pharmaceuticals, Inc. (SPRY) Stock Research Report | Flash
- 🔗 ARS Pharmaceuticals Share Price Today | NASDAQ: SPRY - Investing.com IN
EMPLOYEES198
FOUNDED2015
HQSan Diego, CA, United States
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalPublicAnaphylaxisEpinephrine
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Developed and commercialized neffy, the first FDA-approved needle-free epinephrine nasal spray.
- Headquartered in San Diego with 198 employees and revenue estimated below $1M.
- Completed $410k Rule 144 transaction on NASDAQ as public equity.
- Prior funding included a Series D round in August 2021 and later $100M post-IPO debt.
Ask StreetZero about ARS PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account